PP405 vs RU-58841
Emerging vs Limited Research
compatible Researched · 90% Different mechanisms of action. RU-58841 is a topical androgen receptor antagonist, while PP405 targets stem cell metabolism independently of the androgen pathway. Both are topically applied, but to different molecular targets.
Molecular Data
PP405 RU-58841
Weight ~300-400 Da (exact structure not fully published) 369.34 Da
Half-life Topical application; exact pharmacokinetics not published ~1 hour topically (very short systemic half-life)
Type Small molecule mitochondrial pyruvate carrier (MPC) inhibitor Non-steroidal anti-androgen
Key Benefits
PP405
01 Novel non-hormonal mechanism of action targeting hair follicle stem cell metabolism
02 Directly addresses the root cause of follicle dormancy rather than downstream hormonal effects
03 Potentially effective regardless of androgen status, broadening the treatable population
04 Topical application (0.05% gel) limits systemic exposure
05 Phase 2a results demonstrated increased hair count and thickness
06 Compatible with existing hair loss treatments (finasteride, minoxidil) for combination therapy
07 No known sexual or hormonal side effects based on available trial data
RU-58841
01 Blocks DHT directly at the androgen receptor in hair follicles without reducing systemic DHT levels
02 Extremely short systemic half-life limits risk of systemic anti-androgenic side effects
03 Different mechanism of action from finasteride/dutasteride, allowing combination therapy
04 Animal studies demonstrated significant hair regrowth in androgen-dependent alopecia models
05 Topical application targets the site of action directly
06 Does not interfere with systemic testosterone or DHT levels
Side Effects
PP405
Scalp irritation at the application site
Application site reactions (redness, dryness, itching)
RU-58841
Scalp irritation, dryness, or itching at the application site (often related to the vehicle/solvent rather than RU-58841 itself)
Contact dermatitis in sensitive individuals
Scalp flaking or peeling
Contraindications
Known hypersensitivity to PP405 or any component of the gel formulation
Full contraindication profile has not been established (investigational drug)
Pregnant or breastfeeding women should avoid use until safety data is available
Women who are pregnant or may become pregnant (anti-androgens can cause feminization of a male fetus)
Women who are breastfeeding
Known hypersensitivity to RU-58841 or related non-steroidal anti-androgens
Active scalp infections, open wounds, or severely compromised skin barrier on the scalp
Individuals taking systemic anti-androgens (risk of additive anti-androgenic effects)
Research Evidence
PP405 RU-58841
Status Emerging Limited Research
References 2 studies 4 studies
FDA Approved No No
This comparison is for educational and research purposes only. Consult a healthcare professional before use.